- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00460447
Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation
Gentuzumab Ozogamicin Berfore Allogeneic Stem Cell Transplantation in Patients With Relapsed CD33+ Acute Myeloid Leukemia
Study Design:
prospective phase II trial with 30 patients in 1 site
Treatment Scheme:
Option 1: Patient < 60 years of age with relapse after chemotherapy or > 12 months after hematopoetic stem cell transplantation Mylotarg 6 mg/ m² day -21 Mylotarg 3 mg/ m² day -14 Fludarabin 30 mg/ m² day -6 to -3 TBI 2x2 Gy day -3 to -2 (total dose 8 Gy) Tacrolimus (level adapted) from day -3 on Mycophenolat 2 x 1000 mg p.o. from day 0 to day 40 PBSC day 0
Option 2: Patient > 60 years of age or younger patients < 12 Months after hematopoetic stem cell transplantation Mylotarg 6 mg/ m² day -21 Mylotarg 3 mg/ m² day -14 Fludarabin 30 mg/ m² day -3 to -1 TBI 1x2 Gy day 0 (total dose 2 Gy) Tacrolimus (level adapted) from day -3 on Mycophenolat 2 x 1000 mg p.o. from day 0 to 40 PBSC day 0
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Scientific/Medical Rationale (Objective):
Primary:
documentation of the extramedullary toxicity of the standard therapy
Secondary:
Induction of a persistent remission by the combination of Mylotarg and dose reduced conditioning followed by allogenic hematopoetic stem cell transplantation in patients with relapsed acute myelotic leukemia
Study Design:
prospective phase II trial with 30 patients in 1 site
Treatment Scheme:
Option 1: Patient < 60 years of age with relapse after chemotherapy or > 12 months after hematopoetic stem cell transplantation Mylotarg 6 mg/ m² day -21 Mylotarg 3 mg/ m² day -14 Fludarabin 30 mg/ m² day -6 to -3 TBI 2x2 Gy day -3 to -2 (total dose 8 Gy) Tacrolimus (level adapted) from day -3 on Mycophenolat 2 x 1000 mg p.o. from day 0 to day 40 PBSC day 0
Option 2: Patient > 60 years of age or younger patients < 12 Months after hematopoetic stem cell transplantation Mylotarg 6 mg/ m² day -21 Mylotarg 3 mg/ m² day -14 Fludarabin 30 mg/ m² day -3 to -1 TBI 1x2 Gy day 0 (total dose 2 Gy) Tacrolimus (level adapted) from day -3 on Mycophenolat 2 x 1000 mg p.o. from day 0 to 40 PBSC day 0
Patient Population to be Included:
30 patients
Primary and Secondary Efficacy Endpoints:
See point: Scientific/Medical Rationale
Inclusion Criteria /Exclusion Criteria:
- patients with acute myelotic leukemia and expression of CD33 on > 5% of blasts in bone marrow
- relapse after chemotherapy
- relapse after autologous or allogenic hematopoetic stem cell transplantation
- pts. in 2nd remission after chemotherapy and ineligible for a conventional allogeneic transplantation
- age: 18-70 years
- informed consent of the patient
- ASAT/ ALAT < 3fold of upper standard
- Bilirubin < 2fold of upper standard
- ejection fraction > 40% in echocardiography
- potential donor in accordance with the following priorities:
- 1st HLA-identical related donor (HLA *A, *B, *C and *DR)
- 2nd HLA-identical non-related donor with the maximum of 1 allelmismatch (DNA typing A, B, C, DRB1, DQB1)
Study Procedures:
See point . Study Design
Safety Endpoints/ Statistical Considerations:
Thirty patients will be treated, which will yield a 95% confidence interval for non-relapse mortality with a precision of +/- 14%. Data will be evaluated after groups of 10 and 20 patients. If results at those times suggest with greater than 80% confidence that the true rate of day 100 non-relapse mortality exceeds 20%, then the trial will be stopped. Operationally, this will occur if 4 out of 10 or 7 out of 20 patients have non-relapse deaths. Should the requisite number of deaths be reached before the 10 or 20 patient benchmarks, then the trial will be stopped at that time.
A dose reduction of mylotarg from 9 to 6 mg/m2 will be performed if the likelihood of grade 4 liver-toxicity as defined by bilirubine, AST and symptoms of sinusoidal obstruction syndrome is > 20%. This will be the case if 4 out of the first ten patients experience grade 4 liver toxicity. The second dose of mylotarg will then be omitted in the next ten patients. If the rate of liver-toxicity in the next 10 patients remains unchanged, the study will be stopped.
The stopping rules will be discussed and enforced by the protocol committee and transmitted to each local IRB asap.
The following safety endpoints will be documented:
- Incidence of neurological toxicity
- Incidence of liver toxicity
- Incidence of acute gastrointestinal toxicity
- Incidence and severity of mucositis
- Incidence of pulmonary toxicity
- Incidence of systemic infections
- Duration of neutropenia Severe adverse events (SAE) will have to be reported to the principal investigator within 24 hours after occurrence. It will be his responsibility to inform the IRB and the sponsor or the trial, if adequate.
SAE compromise: death before relapse of leukemia, illness with life-threatening character, severe illness requiring hospitalization, illness leading to prolonged disabilities, second cancer developing after treatment.
SAE will have to be reported on special forms contained in the CRF
Study Type
Enrollment
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Dresden, Germany, 01307
- Recruiting
- Medizinische Klinik und Poliklinik I
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- - patients with acute myelotic leukemia and expression of CD33 on > 5% of blasts in bone marrow
- relapse after chemotherapy
- relapse after autologous or allogenic hematopoetic stem cell transplantation
- pts. in 2nd remission after chemotherapy and ineligible for a conventional allogeneic transplantation
- age: 18-70 years
- informed consent of the patient
- ASAT/ ALAT < 3fold of upper standard
- Bilirubin < 2fold of upper standard
- ejection fraction > 40% in echocardiography
- potential donor in accordance with the following priorities:
- 1st HLA-identical related donor (HLA *A, *B, *C and *DR)
- 2nd HLA-identical non-related donor with the maximum of 1 allelmismatch (DNA typing A, B, C, DRB1, DQB1)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Documentation of the extramedullary toxicity of the standard therapy
|
Secondary Outcome Measures
Outcome Measure |
---|
Induction of a persistent remission by the combination of Mylotarg and dose reduced conditioning followed by allogenic hematopoetic stem cell transplantation in patients with relapsed acute myelotic leukemia
|
Collaborators and Investigators
Investigators
- Principal Investigator: Martin Bornhäuser, MD, Medical Clinic, University Hospital Dresden
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EK 92062003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
Clinical Trials on Gemtuzumab Ozogamicin
-
University Hospital HeidelbergTerminated
-
University of AarhusCompleted
-
PfizerCompletedLeukemiaUnited States
-
PfizerCompletedLeukemia, Myeloid, AcuteUnited States
-
PfizerCompleted
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)UnknownMyelodysplastic SyndromesUnited States
-
European Organisation for Research and Treatment...Gruppo Italiano Malattie EMatologiche dell'AdultoUnknownLeukemiaBelgium, Italy, Netherlands
-
Medical College of WisconsinCompletedRelapsed Adult AMLUnited States
-
Versailles HospitalUnknown
-
PfizerCompletedPharmacokinetics | Safety | ECGCanada, Spain, United States, Hungary, Poland, United Kingdom